secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0000950170-24-083761
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta appoints Nadir Mahmood as President, promotes David Shook to CMO
-----------------------------------------------------------------------

- Nadir Mahmood, former Nkarta CFO and Rezo CEO, appointed President effective July 29, 2024; shares leadership with CEO Paul Hastings.
- David Shook promoted to Chief Medical Officer, Head of R&D, overseeing clinical development, regulatory, and translational science.
- James Trager steps down as Chief Scientific Officer due to personal reasons, transitions to special advisory role.
- Mahmood receives $530K base salary, option for 550K shares vesting over time, 50% target bonus; severance terms included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024083761/0000950170-24-083761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024083761/nktx-20240710.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-083761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer